Carlsmed plans to raise up to $103.3 million through an IPO to support its spine surgery platform, offering 6.7 million shares of common stock. The company sells AI-enabled software and custom implants, aiming to improve alignment and reduce revisions compared to stock implants. Sales increased almost 100% in 2024.

Carlsmed’s products compete with spine implants from larger companies like Medtronic and Johnson & Johnson. The company is growing rapidly, with sales up almost 100% in 2024 and expected to rise again this year. Carlsmed’s platform aims to improve patient outcomes, cut healthcare costs, and address limitations of traditional spine fusion procedures.

Carlsmed’s platform uses AI-enabled algorithms to develop personalized surgical plans and custom interbody implants for each patient, collecting real-world data to improve planning. Evidence shows a lower rate of revision surgery with Carlsmed’s platform compared to stock implants, with revenue up almost 100% in 2024.

Challenges for Carlsmed include a net loss of $24.2 million last year and reliance on a limited number of contract manufacturing organizations. Delays in surgical plans or surgery dates can lead to expedite fees, impacting margins. The company aims to decrease expedite fees by improving operational processes and workflows.

Carlsmed’s IPO filing adds to the increase in medtech IPO activity this year, indicating a potential opening for more companies to list. The success or failure of companies like Carlsmed could impact the IPO window, with some analysts suggesting a backlog of companies waiting to list.

Read more at Yahoo Finance: Carlsmed seeks up to $103M IPO haul to fuel spine surgery growth